(UroToday.com) At the Society of Urologic Oncology (SUO) Summer Virtual Webcast, Dr. Bishoy Faltas from Weill Cornell compared the genetic components of the bladder and upper tract urothelial carcinoma. Upper tract urothelial carcinoma comprises 5-10% of all urothelial carcinomas with a unique epidemiologic association with Arsenic exposure and aristolochic acid. Upper tract urothelial carcinoma presents with muscle invasion (pT2+) in 60% of cases, as compared to 20-30% of cases for bladder urothelial cancer. Upper tract urothelial carcinoma has more advanced disease at presentation but has similar outcomes to patients with bladder cancer after controlling for disease stage. It has been postulated that patients with upper tract urothelial carcinoma have more rapid invasion of the muscularis propria secondary to a thinner wall.